Patent Application for Dispersible Pharmaceutical Formulations

The USPTO has published patent application US20260083690A1 concerning dispersible pharmaceutical formulations of a specific chemical compound. The application details the composition and potential uses of these formulations.

Patent Application for Treating Disease with Dichlorphenamide

The USPTO has published a patent application (US20260083692A1) from Strongbridge Dublin Limited for methods of treating disease using dichlorphenamide in conjunction with an organic anion transporter-1 (OAT1) substrate. The application details methods for administering the compounds and monitoring patient response and toxicity.

Intranasal Pharmaceutical Composition for Migraine Treatment

The USPTO has published a patent application (US20260083693A1) for an intranasal pharmaceutical composition containing ibuprofen and ketoprofen for treating migraine and headaches. The application details a method for manufacturing preparations with a combination of these active ingredients at reduced dosages compared to oral administration.

Composition of L-leucine and fish oil for muscle health

The USPTO has published a patent application (US20260083694A1) for a composition comprising L-leucine and fish oil, intended for muscle health and the prevention of muscle mass and strength loss. The application was filed by ABIOGEN PHARMA S.P.A.

Patent Application: Composition for Mitigating Veisalgia and Nausea

The USPTO has published a patent application (US20260083695A1) for a composition designed to reduce veisalgia (hangover) symptoms and nausea. The application details an orally deliverable formulation containing dihydromyricetin, acetylcysteine, and specific antiemetics, with a filing date of September 10, 2025.

Gamma-hydroxybutyrate Formulations with Improved Pharmacokinetics

The USPTO has published a new patent application, US20260083696A1, detailing modified release formulations of gamma-hydroxybutyrate with improved dissolution and pharmacokinetic properties. The application was filed on October 1, 2025, by inventors Jordan Dubow, Claire Megret, Hervé Guillard, and Jean-François Dubuisson.

Patent Application: Composition for Controlling Aquatic Organism Infections

The USPTO has published a new patent application (US20260083697A1) from B. G. Negev Technologies and Applications Ltd. The application details a composition containing an esterified fatty acid for preventing or treating monogenean infections in aquatic organisms.

Patent Application: Synergistic Stimulation for Cystic Fibrosis Mucus Obstruction

The USPTO has published a new patent application (US20260083698A1) detailing methods for treating mucus obstruction in cystic fibrosis and other disorders. The application, filed on September 19, 2023, describes a combination therapy involving a b-adrenergic agonist or adenylate cyclase activator with a cholinergic agonist.

Patent Application for Psychoactive Medicines Treating Disorders

The USPTO has published patent application US20260083699A1 by Transcend Therapeutics, Inc. The application details psychoactive medicines, including 2C-B and cathinones, for treating psychiatric and neurological conditions. The filing date was December 4, 2025.

Patent Application: Methods Treat/Prevent Protein Aggregation Diseases Using Sulfatase Inhibitor

The USPTO has published a new patent application (US20260083700A1) detailing methods for treating and/or preventing protein-aggregation diseases by administering a sulfatase inhibitor. The application was filed on September 26, 2025, by inventors Manuel J. Muñoz, Ángel M. Carrión, and Mercedes M. Pérez-Jiménez.